10.20.25 -- Outsourcing: You Own It, They Earn It

This webinar explores how next-generation cell line platforms streamline biologic development. Experts from Abzena, Revvity, and ProteoNic discuss flexible CLD strategies, integrated analytics, and technologies like AbZelectPRO™ and CHOSOURCE™ to boost productivity, achieve high-quality titers, reduce timelines, and de-risk scale-up, helping developers efficiently bring therapeutic antibodies and difficult-to-express proteins to the clinic. Click here to learn more.

Targeted modalities are pushing the boundaries of technology and therapeutic effectiveness. Their potential to transform patient care depends on the right expertise, tech, and partnerships.

Assessing outsourcing partners’ credentials in people, technology, supply chains, and integration will make all the difference as sponsors aim to streamline processes on the path to commercialization.

Stringent QC release testing throughout biologic production, as mandated by health authorities, ensures product safety and quality through evaluations of identity, purity, potency, and critical quality attributes.

The United States Pharmacopeia is overhauling general chapters to align them with current industry standards. One scientist on the project helps us unpack the changes.

Examine why it is essential for biotechs to choose the right contract development and manufacturing partner for drug development success in this market landscape.

Explore regulatory framework and expectations, and see the benefit of a comprehensive approach to CCI tailored for mAbs and complex modalities such as fusion proteins or bioconjugates.

The greatest challenge in drug development can be finding a team capable of carrying a molecule through the complexities that lie between the research lab and the patient’s bedside.

See how AI-powered predictive maintenance with wireless vibration sensors prevented costly batch loss and production shutdowns by detecting and fixing equipment issues before failures occurred.

See how the recently described cell line development paradigm shift, enabled by the Leap-In transposon platform, can extend to the development of bispecific monoclonal antibody-producing cell substrates.

We bring over two decades of cell line development (CLD) experience together with state-of-the-art technologies to ensure every step is strategically designed and meticulously executed.

Review the regulatory expectations for biopharmaceutical characterization along with the specific requirements for some of the more common modalities that are currently in development.

With over 20 years of experience, see why we're the ideal partner for emerging biopharmaceutical companies seeking to develop and launch injectable therapeutics efficiently and cost-effectively.